Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides

Neurobiology of Aging

Volumn 17, Issue 5, 1996, Pages 773-780

  Ma, Jianyi ^b   Brewer Jr , H Bryan ^b   Potter, Huntington ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

ACT; Acute phase response; Alzheimer's disease; Amyloid; apoE; IL 1; Inflammation

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; INTERLEUKIN 1;

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0000448998     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-4580(96)00112-1     Document Type: Article

References (88)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501; 1988.
2. 1-Antichymotrypsin is present together with the β-protein in monkey brain amyloid deposits. Neuroscience 32:715-720; 1989.
3. 1-antichymotrypsin is associated solely with amyloid deposits containing the β-protein and is localized in specific cells of both normal and diseased brain. Neurobiol. Aging 11:123-129; 1990.
4. 4. Burgevin, M.-C.; Passat, M.; Daniel, N.; Capet, M.; Doble, A. Congo Red protects against toxicity of β-amyloid peptides on rat hippocampal neurones. Neuroreport 5:2429-2432; 1994.
5. 5. Busciglio, J.; Lorenzo, A.; Yankner, B. A. Methodological variables in the assessment of beta amyloid neurotoxicity. Neurobiol. Aging 13: 609-612; 1992.
6. 6. Cacabelos, R.; Alvarez, X. A.; Fernandez-Novoa, L.; Franco, A.; Mangues, R.; Pellicar, A.; Nishimura, T. Brain interleukin-1β in Alzheimer's disease and vascular dementia. Methods Find. Exp. Clin. Pharmacol. 16:141-151; 1994.
7. 7. Cai, X.-D.; Golde, T. E.; Younkin, S. G. Release of excess amyloid β protein from a mutant β protein precursor. Science 259:514-5161 1993.
8. 8. Castaño, E. M.; Ghiso, J.; Prelli, F.; Gorevic, P. D.; Migheli, A.; Frangione, B. In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease β-protein. Biochem. Biophys. Res. Commun. 141:782-789; 1986.
9. 9. Chartier-Harlin M.-C.; Crawford, F.; Houlden, H.; Warren, A.; Hughes, D.; Fidandi, L.; et al. Early onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353:844-846; 1991.
10. 10. Chartier-Harlin, M.-C.; Parfitt, M.; Legrain, S.; Perez-Tur, J.; et al. Apolipoprotein E, E4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: Analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet. 3:569-574; 1994.
11. 11. Citron, M.; Oltersdorf, T.; Haass, C.; McConlogue, L.; Hung, A. Y.; Seubert, P.; et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's diseases increases β-protein production. Nature 360:672-674; 1992.
12. 12. Corder, E. H.; Saunders, A. M.; Strittmatter, W. J.; Schmechel, D. E.; et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923; 1993.
13. 13. Corder, E. H.; Saunders, A. M.; Risch, N. J.; Strittmatter, W. J.; et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7:180-184; 1994.
14. 14. Das, S.; Potter, H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron 14:447-456; 1995.
15. 15. Döbeli, H.; Draeger, N.; Huber, G.; Jakob, P.; et al. A biotechnological method provides access to aggregation component monomeric Alzheimer's 1-42 residue amyloid peptide. Biotechniques 13:988-993; 1995.
16. 16. Dovey, H. F.; Suomensaari-Chrysler, S.; Lieberburg, I.; Sinha, S.; Keim, P. S. Cells with a familial Alzheimer's disease mutation produce authentic β-peptide. Neuroreport 4:1039-1042; 1993.
17. 1antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA 92:2313-2317; 1995.
18. 18. Evans, K. C.; Berger, E. P.; Cho, C.-G.; Weisgraber, K. H.; Lansbury, P. T. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 92:763-767; 1995.
19. 1antichymotrypsin deficiency in a heterozygote with liver and lung disease. J. Hepatol. 18:313-321; 1993.
20. 20. Fasman, G. D.; Perczel, A.; Moore, C. D. Solubilization of β amyloid-(1-42) peptide: Reversing the β-sheet conformation induced by aluminum with silicates. Proc. Natl. Acad. Sci. USA 92:369-371; 1995.
21. 1antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 61:298-305; 1993.
22. 22. Glenner, G. G.; Wong, C. W. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 122:885-890; 1984.
23. 23. Goate, A.; Chartier-Harlin, M.-C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer disease. Nature 349:704-706; 1991.
24. 24. Gregg, R. E.; Zech, L. A.; Schaefer, E. J.; Stark, D.; Wilson, D.; Brewer, H. B. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78:815-821; 1986.
25. 25. Griffin, W. S. T.; Stanley, L. C.; Ling, C.; et al. Brain interleukin-1 and S100 immunoreactivity elevated in Down's syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 86:7611-7615; 1989.
26. 26. Griffin, W. S. T.; Sheng, J. G.; Roberts, G. W.; Mrak, R. E. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54: 276-281; 1995.
27. 27. Hendriks, L.; Van Duijn, C. M.; Cras, P.; et al. Presenile dementia and cerebral hemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat. Genet. 1:218-221; 1992.
28. 28. Higaki, J.; Quon, D.; Zhong, Z.; Cordell, B. Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14:651-659; 1995.
29. 29. Hyman, B. T.; West, H. L.; Rebeck, G. W.; Buldyrev, S. V.; Mantegna, R. N.; Ukleja, M.; Havlin, S.; Stanley, H. E. Quantitative analysis of senile plaques in Alzheimer disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc. Natl. Acad. Sci. USA 92:3586-3590; 1995.
30. 30. Iwatsubo, T.; Odaka, A.; Suzuki, N.; Mizusawa, H.; Nukina, N.; Ihara, Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 13:45-53; 1994.
31. 31. Jarrett, J. T.; Lansbury, P. T. Seeding "one-dimensional crystalization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-1058; 1993.
32. 32. Jarrett, J. T.; Berger, E. P.; Lansbury, P. T. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697; 1993.
33. 1antichymotrypsin polymorphism. Nat. Genet. 10:486-488; 1995.
34. 34. Kirschner, D. A.; Inouye, H.; Duffy, L. K.; Sinclair, A.; Selkoe, D. J. Synthetic β-peptide of Alzheimer disease forms amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. USA 84:6953-6957; 1987.
35. 35. Kisilevsky, R.; Lemieux, L. J.; Fraser, P. E.; Kong, X.; Hultin, P. G.; Szarek, W. A. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. Nat. Med. 1:143-148; 1995.
36. 1antichymotrypsin in brain may be related to astrogliosis. Neurobiol. Aging 12:495-501; 1991.
37. 37. Lannfelt, L.; Lilius, L.; Nastase, M.; Viitanen, M.; et al. Lack of association between apolipoprotein E allele E4 and sporadic Alzheimer's disease. Neurosci. Lett. 169:175-178; 1994.
38. 38. Levy, E.; Carman, M. D.; Fernandez-Madrid, I. J.; Power, M. D.; Lieberburg, I.; Van Duinen, S. G.; Bots, G. T. A. M.; Luyendijk, W.; Frangione, B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, dutch type. Science 248:1124-1126; 1990.
39. 39. Levy-Lahad, E.; Wijsman, E. M.; Nemens, E.; Anderson, L.; Goddard, K. A. B.; Weber, J. L.; Bird, T. D.; Schellenberg, G. D. A familial Alzheimer's disease locus on chromosome 1. Science 269:970-973; 1995.
40. 40. Levy-Lahad, E.; Wasco, W.; Poorkaj, P.; Romano, D. M.; Oshima, J.; Pettingell, W. H.; Yu, C.-E.; Jondro, P. D.; Schmidt, S. D.; Wang, K.; Crowley, A. C.; Fu, Y.-H.; Guenette, S. Y.; Galas, D.; Nemens, E.; Wijsman, E. M.; Bird, T. D.; Schellenberg, G. D.; Tanzi, R. E. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973-977; 1995.
41. 41. Li, J.; Ma, J.; Potter, H. A potential familial Alzheimer's disease gene on chromosome 1 related to AD3. Proc. Natl. Acad. Sci. USA 92: 12180-12184; 1995.
42. 42. Liepnieks, J. J.; Ghetti, B.; Farlow, M.; Roses, A. D.; Benson, M. D. Characterization of amyloid fibril β-peptide in familial Alzheimer's disease with APP717 mutations. Biochem. Biophys. Res. Commun. 197:386-392; 1993.
43. 43. Lorenzo, A.; Yankner, B. A. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Natl. Acad. Sci. USA 91:12243-12247; 1994.
44. 1antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372:92-94; 1994.
45. 45. Maestre, G.; Ottman, R.; Stern, Y.; Gurland, B.; et al. Apolipoprotein E and Alzheimer's disease: Ethnic variation in genotype risks. Ann. Neurol. 37:254-259; 1995.
46. 46. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63; 1983.
47. 47. Mullan, M.; Crawford, F.; Axelman, K.; Houlden, H.; Lulius, L.; Winblad, B.; Lannfelt, L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid. Nat. Genet. 1:345-347; 1992.
48. 48. Namba, Y.; Tomonaga, M.; Kawasaki, H.; Otomon, E.; Ikeda, K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:163-166; 1991.
49. 49. Näslund, J.; Schierhorn, A.; Hellman, U.; Lannfelt, L.; Roses, A. D.; et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA 91:8378-8382; 1994.
50. 50. Ohm, T. G.; Kirca, M.; Bohl, J.; Scharnagl, H.; Groß, W.; März, W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 66:583-587; 1995.
51. 1antichymotrypsin mRNA. Am J. Pathol. 32:715-720; 1989.
52. 52. Pericak-Vance, M. A.; Bebout, J. L.; Gaskell, P. C.; Yamaoka, L. H.; et al. Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. Am. J. Hum. Genet. 48:1034-1050; 1991.
53. 1antichymotrypsin in cerebral and systemic amyloid. J. Neuropathol. Exp. Neurol. 49:41-48; 1990.
54. 54. Pike, C. J.; Walencewicz, A. J.; Glabe, C. G.; Cotman, C. W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:311-314; 1991.
55. 55. Pike, C. J.; Burdick, D.; Walencewicz, A. J.; Glabe, C. G.; Cotman, C. W. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13:1676-1687; 1993.
56. 1antichymotrypsin gene associated with chronic lung disease. Lancet 339:1538; 1992.
57. 1antichymotrypsin and β-protein form a stable complex in vitro. In: Iqbal, K.; MacLachlan, D. R. C.; Winblad, B.; Wisniewski, H. M., eds. Alzheimer's disease: Basic mechanisms, diagnosis, and therapeutic strategies. New York: John Wiley & Sons; 1991:275-279.
58. 58. Potter, H.; Nelson, R. B.; Das, S.; Siman, R.; Kayyali, U. S.; Dressler, D. The involvement of proteases, protease inhibitors, and an acute phase response in Alzheimer's disease. Ann. NY Acad. Sci. 674:161-173; 1992.
59. 59. Potter, H.; Ma, J.; Das, S.; Geller, L. N.; Benjamin, M.; Kayyali. U. S.; Dressler, D. Beyond β-protein: New steps in the pathogenic pathway to Alzheimer's disease. In: Iqbal, K.; Mortimer, J. A.; Winblad, B.; Wisniewski, W. H., eds. Research advances in Alzheimer's disease and related disorders. New York: John Wiley & Sons; 1995:643-654.
60. 60. Rebeck, G. W.; Reiter, J. S.; Strickland, D. K.; Hyman, B. T. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11:575-580; 1993.
61. 61. Rogaev, E. I.; Sherrington, R.; Rogaeva, E. A.; Levesque, G.; Ikeda, M.; Liang, Y.; Chi, H.; Lin, C.; Holman, K.; Tsuda, T.; Mar, L.; Sorbl, S.; Nacmias, B.; Piacentini, S.; Amaducci, L.; Chumakov, I.; Cohen, D.; Lannfelt, L.; Fraser, P.E.; Rommens, J. M.; St. George-Hyslop, P. H. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775-778; 1995.
62. 62. Roher, A. E.; Lowenson, J. D.; Clarke, S.; Woods, A. S.; Cotter, R. J.; Gowing, E.; Ball, M. J. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90:10836-10840; 1993.
63. 63. Rozemuller, J. M.; Stam, F. C.; Eikelenboom, P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci. Lett. 119:75-78; 1990.
64. 1antichymotrypsin. Acta Neuropathol. 82:200-207; 1991.
65. 65. Sanan, D. A.; Weisgraber, K. H.; Russell, S. J.; Mahley, R. W.; Huang, D.; et al. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. J. Clin. Invest. 94:860-869; 1994.
66. 66. Schellenberg, G. D. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc. Natl. Acad. Sci. USA 92:8552-8559; 1995.
67. 67. Schellenberg, G. D.; Bird, T. D.; Wijsman, E. M.; Orr, H. T.; Anderson, L.; Nemens, E.; White, J. A.; Bonnycastle, L.; Weber, J. L.; Alonsa, M. E.; Potter, H.; Heston, L. L.; Martin, G. M. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258:668-671; 1992.
68. 68. Schmechel, D. E.; Saunders, A. M.; Strittmatter, W. J.; Grain, B. J.; et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:9649-9653;1993.
69. 69. Schwartzman, A. L.; Gregori, L.; Vitek, M. P.; Lyubski, S.; et al. Transthyretin sequesters amyloid β protein and prevents amyloid formation. Proc. Natl. Acad. Sci. USA 91:8368-8372; 1994.
70. 70. Selkoe, D. J. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10:373-403; 1994.
71. 71. Sherrington, R.; Rogaev, E. I.; Liang, Y.; Rogaeva, E. A.; Levesque, G.; et al. Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature 375:754-760; 1995.
72. 1antichymotrypsin is present in diffuse senile plaques. Am. J. Pathol. 138:247-257; 1991.
73. 73. Song, X.-H.; Suzuki, N.; Bird, T.; Peskind, E.; Schellenberg. G. D.; Younkin, S. G. Plasma amyloid β-protein (Aβ) ending at Aβ42(43) is increased in carriers of familial AD (FAD) linked to chromosome 14. Soc. Neurosci. Abstr. 21:1501; 1995.
74. 74. St. George-Hyslop, P.; Haines, J.; Rogaev, E.; Mortilla, M.; Vaula, G.; et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat. Genet. 2:330-334; 1992.
75. 75. Strittmatter, W. J.; Saunders, A. M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G. S.; Roses, A. D. Apolipoprotein E: High affinity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:1977-1981; 1993.
76. 76. Suzuki, N.; Cheung, T. T.; Cai, M.-D.; Odaka, A.; Otvos, L.; Eckman, C.; Golde, T. E.; Younkin, S. G. An increased percentage of long amyloid β-protein by familial amyloid β-protein precursor (βAPP717) mutants. Science 264:1336-1340; 1994.
77. 77. Tamaoka, A.; Odaka, A.; Ishibashi, Y.; Usami, M.; Sahara, N.; Suzuki, N.; Nukina, N.; Mizusawa, H.; Shoji, S.; Kanazawa, I.; Mori, H. APP717 missence mutation affects the ratio of amyloid β protein species (Aβ1-42/43 and Aβ1-40) in familial Alzheimer's disease brain. J. Biol. Chem. 269:32721-32724; 1994.
78. 78. Ueda, K.; Fukui, Y.; Kageyama, H. Amyloid β protein-induced neuronal cell death: Neurotoxic properties of aggregated amyloid β protein. Brain Res. 639:240-244; 1994.
79. 79. Van Broeckhoven, C.; Hann, J.; Bakker, E.; Hardy, J. A.; Van Hul, W.; Wehnert, A.; Vegter-Van der Vlis, M.; et al. Amyloid β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 248:1120-1122; 1990.
80. 80. Van Broeckhoven, C.; Backhovens, H.; Cruts, M.; De Winter, G.; Bruyland, M.; Cras, P.; Martin J.-J. Mapping of a gene predisposing to early onset Alzheimer's disease to chromosome 14q24.3. Nat. Genet. 2:335-339;1992.
81. 81. Van Broeckhoven, C.; Backhovens, H.; Cruts, M.; Martin, J. J.; Crook, R.; Houlden, H.; Hardy, J. ApoE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci. Lett. 169:179-180; 1994.
82. 82. Van Duijn, C. M.; de Knijff, P.; Wehnert, A.; De Voecht, J.; et al. The apolipoprotein E ∈2 allele is associated with an increased risk of early onset Alzheimer's disease and a reduced survival. Ann. Neurol. 37: 605-610; 1995.
83. 83. Wisniewski, T.; Ghiso, J.; Frangione, B. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem. Biophys. Res. Commun. 179:1247-1254; 1991.
84. 84. Wisniewski, T.; Frangione, B. Apolipoprotein E: A pathologic chaperone in patients with cerebral and systemic amyloid. Neurosci. Lett. 135:235-238; 1992.
85. 85. Wisniewski, T.; Golabek, A.; Matsubara, E.; Ghiso, J.; Frangione, B. Apolipoprotein E: Binding to soluble Alzheimer's β-amyloid. Biochem. Biophys. Res. Commun. 192:359-365; 1993.
86. 86. Wisniewski, T.; Castaño, E. M.; Golabek, A.; Vogel, T.; Frangione, B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1030-1035; 1994.
87. 87. Yankner, B. A.; Mesulam, M.-M. β-Amyloid and the pathogenesis of Alzheimer's disease. N. Engl. J. Med. 325:1849; 1991.
88. 88. Yankner, B. A.; Duffy, L. K.; Kirschner, D. A. Neurotrophic and neurotoxic effects of amyloid β-protein: Reversal by tachykinin neuro-peptides. Science 250:280-282; 1990.